GuidelinesOther guideline
Community Acquired S.aureus Bacteraemia
Infection Community acquired S.aureus bacteraemia Brief outline/clinical setting S. aureus is a leading cause of bacteraemia, infective endocarditis, osteoarticular, skin and soft tissue and pleuropulmonary infections. Aetiologies/organisms S.aureus Optimal antimicrobial selection Cloxacillin 2g IVI bolus, then 2g IVI 6hrly as extended infusion where possible. If infusion is not possible, dosing
| Infection | Community acquired S.aureus bacteraemia |
|---|---|
| Brief outline/clinical setting | S. aureus is a leading cause of bacteraemia, infective endocarditis, osteoarticular, skin and soft tissue and pleuropulmonary infections. |
| Aetiologies/organisms | S.aureus |
| Optimal antimicrobial selection | Cloxacillin 2g IVI bolus, then 2g IVI 6hrly as extended infusion where possible. If infusion is not possible, dosing should ideally should be 4hrly |
| Duration | Minimum 2 weeks for confirmed S.aureus bacteraemia, total duration dependent on investigations for IE and deep seated sources of infection - Most important would be normalisation of CRP |
| Alternative if allergic/not available | Cefazolin 1- 2g IVI 8hrly |
| Rationale | For Cefazolin- Non-availability of cloxacillin. Also evidence showing that cefazolin is superior to anti-staphylococcal penicillins for bacteraemia in the absence of endocarditis or high burden(inoculum) infections. |
| Level of evidence | High |
| Link to Guideline | Click here |